All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
For Poseida Therapeutics Inc., a new global license agreement with Janssen Biotech Inc., a unit of Johnson & Johnson, to discover, develop, manufacture and commercialize chimeric antigen receptor (CAR) T-cell-based therapies is a signal that "everything's unfolding according to plan," observed Eric Ostertag, Poseida's founder and CEO.